06872 丹諾醫藥－B
TENNOR THERAP-B
TENNOR THERAP-B
| Register Close | 2026/05/19 IPO Closing in 5 Days |
| Listing Date | 2026/05/22 |
|
|
|
|
|
|
|
|
|
|
IPO Detail
COMPANY PROFILE
TenNor Therapeutics (Suzhou) Limited was incorporated in 2013, it is a near-commercial stage biotechnology company dedicated to the discovery, development and commercialization of differentiated therapies to address medical needs in disease areas associated with bacterial infections and bacterial metabolism.
--
As of May 4, 2026, the Group had built a pipeline of seven innovative programs, including two Core Products, it had 41 registered trademarks, and 25 domain names; 42 issued patents, and 85 patent applications.
--
Rifasutenizol (TNP-2198), a Core Product, is a new molecular entity (“NME”) drug candidate used as part of a triple therapy in combination with amoxicillin and a proton pump inhibitor for the treatment of Helicobacter pylori (“H. pylori”) infection in China and U.S. as well as monotherapy for bacterial vaginosis and C. difficile infection in China.
--
Rifaquizinone (TNP-2092 injection), a Core Product, is a triple-targeting antibacterial drug candidate for the treatment of implant-associated bacterial infections, i.e. acute bacterial skin and skin structure infection (“ABSSSI”) and prosthetic joint infection (“PJI”), as well as left ventricular assist device infection (“LVADI”) and catheter-related bloodstream infection (“CRBSI”) in China and the U.S.
BASIC INFORMATION
| Market | Hong Kong (Main Board) |
| Business Nature | Health Care |
| Major Business Area | China |
| Board Lot | 50 |
GLOBAL OFFERING
| No. of Offer Shares | 8.28M H shares |
| No. of International Offer Shares | 7.45M H shares |
| No. of HK Offer Shares | 0.83M H shares |
| Offer Price | $75.70 |
| Stock Code | 6872 |
| Sponsor(s) | CITIC Securities (Hong Kong) Limited, ABCI Capital Limited |
| Underwriter(s) | CLSA Limited, ABCI Securities Company Limited, China Renaissance Securities (Hong Kong) Limited, Futu Securities International (Hong Kong) Limited, Tiger Brokers (HK) Global Limited |
TIME TABLE
| Application Period | May 14 (Thu) - noon, May 19 (Tue) |
| Price Determination Date | -- |
| Result Announcement Date | On or before May 21 (Thu) |
| Result Announcement Date | On or before May 21 (Thu) |
| Result Announcement Date | On or before May 22 (Fri) |
| Dealings in Shares commence on | May 22, 2026. (Fri) |
Reallocation of Shares Offered
Sales Statistics (HKD)
| Offer Price | $75.70 |
| Capitalization | 3.92B |
| NAV / share ($) | $14.00 (Unaudited pro forma adj NAV / share) |
Use Of Proceeds
| Assuming the offer price being at HKD 75.7, the net proceeds raised would be HKD 557.80M, of which |
| 71% : Research, development, registrational filings and commercialization of Core Products |
| 7% : Research and development of TNP-2092 oral formulation |
| 7.3% : Research and development of other product candidates |
| 7.2% : Construction of in-house manufacturing facility |
| 7.5% : Working capital |
Related Document
| Prospectus |  Chinese Version | English Version |
| Remark： | The above information is referenced from the prospectus. |
| All data is calculated from the non- exercise rights(if applicable). |
Name︰
--
--
--
Subscription --
Result Announcement --
Listing --Offer Price︰--
| Currency | : |
| Listing Price | : |
| Board Lot | : |
| Admission Fee* |
: |
| Subscribing Lot | : |
| Subscribing Fee | : |
| Subscribing Amount | : |
*Admission fees include brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015% (i.e. 1.0077% in total).